Nymox Pharmaceutical Corpの簿価
Nymox Pharmaceutical Corpの簿価 は何ですか。
Nymox Pharmaceutical Corpの簿価 は0.01です。
簿価 の定義は何ですか。
1株当たりの帳簿価額は、会社の資産から会社の負債を差し引いた数を発行済株式数で割ったものです。
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
NASDAQのセクタHealth Careにおける簿価 の企業と比べるNymox Pharmaceutical Corp
Nymox Pharmaceutical Corpは何をしますか。
nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.
Nymox Pharmaceutical Corpと類似の簿価
- Sulliden Mining Capitalの簿価 は0.01です。
- Metro Miningの簿価 は0.01です。
- Code Agriculture ()の簿価 は0.01です。
- Aveniraの簿価 は0.01です。
- Voyageur Pharmaceuticalsの簿価 は0.01です。
- KORE Miningの簿価 は0.01です。
- Nymox Pharmaceutical Corpの簿価 は0.01です。
- Battery Mineralsの簿価 は0.01です。
- Metalsearchの簿価 は0.01です。
- Versarien plcの簿価 は0.01です。
- Fuse Cobalt Incの簿価 は0.01です。
- Resolve Venturesの簿価 は0.01です。
- WLSの簿価 は0.01です。